Innovation in Cipla Essay
Innovation in Cipla
It was founded by nationalist Indian scientist Khwaja Abdul Hamied as The Chemical, Industrial & Pharmaceutical Laboratories in 1935, with a vision to make India self-sufficient in supplying medicine to its people. It is one of the world’s largest generic companies with over 2,000 products, 65 therapeutic categories, over 40 dosage forms. Cipla makes drugs to treat cardiovascular disease, arthritis, diabetes, weight control, depression and many other health conditions, and its products are distributed in virtually every country of the world. Cipla is the world’s largest manufacturer of antiretroviral drugs to fight HIV/AIDS.
It has 34 state-of-the-art manufacturing facilities approved by major international regulatory agencies. Continuous innovation and R&D has been the characteristic of Cipla. Cipla exports to more than 185 countries in all corners of the world. Company’s philosophy: “We believe there’s no use in developing life-saving medicines if we can’t make them affordable for the patient” Cipla has always emphasized self-reliance and the right of all people to health and access to medicine, regardless of their economic circumstances or where in the world they happen to live. Revenue: Rs.6,977.50 crore (US$1.27 billion)
Chairman: Y. K. Hamied
1935: Dr K A Hamied sets up “The Chemical, Industrial and Pharmaceutical Laboratories Ltd.” in a rented bungalow at Bombay Central. 1941: As the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities to the war effort. 1952: Sets up first research division for attaining self-sufficiency in technological development. 1960: Starts operations at second plant at Vikhroli, Mumbai, producing fine chemicals with special emphasis on natural products. 1968: Cipla manufactures ampicillin for the first time in the country. 1972: Starts Agricultural Research Division at Bangalore, for scientific cultivation of medicinal plants. 1976: Cipla launches medicinal aerosols for asthma.
1982: Fourth factory begins operations at Patalganga, Maharashtra. 1984:
Develops anti-cancer drugs, vinblastine and vincristine in collaboration with the National Chemical Laboratory, Pune. 1985: US FDA approves Cipla’s bulk drug manufacturing facilities. 1991: Launches etoposide, zidovudine a breakthrough in cancer chemotherapy, in association with Indian Institute of Chemical Technology. 1994: Cipla’s fifth factory begins commercial production at Kurkumbh, Maharashtra. 1997: Launches transparent Rotahaler, the world’s first such dry powder inhaler device now patented by Cipla in India and abroad. 1997: The palliative cancer care centre set up by the Cipla Foundation, begins offering free services at Warje, near Pune. 1998: Launches lamivudine, becoming one of the few companies in the world to offer all three component drugs of retroviral combination therapy (zidovudine and stavudine already launched). 1999: Launches Nevirapine, antiretroviral drug, used to prevent the transmission of AIDS from mother to child. 2000: Cipla became the first company, outside the USA and Europe to launch CFC-free inhalers – ten years before the deadline to phase out use of CFC in medicinal products. 2001:
Cipla announces it is prepared to supply a triple antiretroviral (ARV) combination for $350 per patient per year in poor countries. Prices for equivalent combinations at the time ranged up to over $15,000 per year in price. 2002: Four state-of-the-art manufacturing facilities set up in Goa 2003: Launches TIOVA (Tiotropium bromide), a novel inhaled, long-acting anticholinergic bronchodilator that is employed as a once-daily maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). 2005: Set-up state-of-the-art facility for manufacture of formulations at Baddi, Himachal Pradesh. 2007: Set-up state-of-the-art facility for manufacture of formulations at Sikkim. 2010: Set up state-of-the-art facility for manufacture of formulations at Indore. 2012: Announces price cuts averaging 75% on a range of complex cancer drugs. Important factors for Cipla’s success:
Cipla’s R&D: Cipla along with a great research team allowed expense of 5% of its annual income for R&D which reaped innovation, which lead to increased revenue generation, increased market goodwill, increasing company value and most importantly better treatment of existing diseases. This was the important factor for Cipla’s success. Some of the products of R&D are as follows: 1. 1968: Cipla manufactures ampicillin for the first time in the country. Ampicillin was a relatively newer and one of the few antibiotics in 1960’s. India which was struggling to come up after just two decade of its independence was in acute shortage of medicines. With a vision of “Making India self sufficient for medicines”, Cipla saw the opportunity and started manufacture of ampicillin. This led to increased revenues for the company. 2. 1997:
Launches transparent Rotahaler, the world’s first such dry powder inhaler device now patented by Cipla in India and abroad. Asthma is commonly prevelant disease in world. Inhalation route of drug delivery is the most efficient to reduce the complications. However, only a fewer devices were available for administration through inhalation in 1990’s. Cipla, with continuous R&D in Asthma metered dose inhalers, made a breakthrough by discovering and launching transparent Rotahaler, the world’s first such dry powder inhaler device. With this, Cipla’s Rotahaler became the choice for Asthma management. Rotahaler posted huge increase in revenues.
Cipla became very well known to the market increasing its goodwill, company value. 3. 1998: Launches Triomune and Duovir-N, becoming one of the few companies in the world to offer all three component drugs of retroviral combination therapy Cancer, known to be the disease of our ages, was considered to be untreatable. With continuous Research and development in the dosage form technology of anti retroviral drugs, Cipla pioneered three-in-one tablet called Triomune and Duovir-N containing a fixed-dose combination (FDC) of three Anti retroviral drugs i.e. Lamivudine, stavudine, Nevirapine and Lamivudine, Zidovudine, Nevirapine respectively.
University/College: University of Arkansas System
Type of paper: Thesis/Dissertation Chapter
Date: 1 October 2016
Let us write you a custom essay sample on Innovation in Cipla
for only $16.38 $13.9/page